Integrated Biopharma Stock Gross Profit
INBPDelisted Stock | USD 0.23 0.01 4.55% |
Integrated Biopharma fundamentals help investors to digest information that contributes to Integrated Biopharma's financial success or failures. It also enables traders to predict the movement of Integrated OTC Stock. The fundamental analysis module provides a way to measure Integrated Biopharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Integrated Biopharma otc stock.
Integrated |
Integrated Gross Profit Analysis
Integrated Biopharma's Gross Profit is the most basic measure of business operational efficiency. It is simply the difference between sales revenue and the cost associated with making a product or providing a service. It is calculated before deducting administrative expenses, taxes, and interest payments.
Current Integrated Biopharma Gross Profit | 6.55 M |
Most of Integrated Biopharma's fundamental indicators, such as Gross Profit, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Integrated Biopharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Gross Profit varies significantly from one sector to another and tells an investor how much money a business would have made if it didn't have to pay any overhead expenses such as salary, taxes, or rent.
CompetitionAccording to the company disclosure, Integrated Biopharma reported 6.55 M of gross profit. This is 99.93% lower than that of the Personal Products sector and 99.63% lower than that of the Consumer Staples industry. The gross profit for all United States stocks is 99.98% higher than that of the company.
Integrated Gross Profit Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Integrated Biopharma's direct or indirect competition against its Gross Profit to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Integrated Biopharma could also be used in its relative valuation, which is a method of valuing Integrated Biopharma by comparing valuation metrics of similar companies.Integrated Biopharma is currently under evaluation in gross profit category among related companies.
Integrated Fundamentals
Return On Equity | 0.13 | ||||
Return On Asset | 0.0336 | ||||
Profit Margin | 0.04 % | ||||
Operating Margin | 0.03 % | ||||
Current Valuation | 12.05 M | ||||
Shares Outstanding | 29.95 M | ||||
Shares Owned By Insiders | 68.58 % | ||||
Shares Owned By Institutions | 0.06 % | ||||
Price To Earning | 2.52 X | ||||
Price To Book | 0.56 X | ||||
Price To Sales | 0.21 X | ||||
Revenue | 56.25 M | ||||
Gross Profit | 6.55 M | ||||
EBITDA | 3.54 M | ||||
Net Income | 3.84 M | ||||
Cash And Equivalents | 343 K | ||||
Cash Per Share | 0.01 X | ||||
Total Debt | 53 K | ||||
Debt To Equity | 0.11 % | ||||
Current Ratio | 3.16 X | ||||
Book Value Per Share | 0.62 X | ||||
Cash Flow From Operations | 4.09 M | ||||
Earnings Per Share | 0.11 X | ||||
Number Of Employees | 147 | ||||
Beta | 0.52 | ||||
Market Capitalization | 11.2 M | ||||
Total Asset | 25.25 M | ||||
Retained Earnings | (59.89 M) | ||||
Working Capital | 913 K | ||||
Current Asset | 12.7 M | ||||
Current Liabilities | 11.79 M | ||||
Net Asset | 25.25 M |
About Integrated Biopharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Integrated Biopharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Integrated Biopharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Integrated Biopharma based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Integrated BioPharma, Inc., together with its subsidiaries, manufactures, distributes, markets, and sells vitamins, nutritional supplements, and herbal products primarily in the United States and Luxembourg. Integrated BioPharma, Inc. was incorporated in 1980 and is based in Hillside, New Jersey. Integrated Biopharma operates under Packaged Foods classification in the United States and is traded on OTC Exchange. It employs 147 people.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of labor statistics. Note that the Integrated Biopharma information on this page should be used as a complementary analysis to other Integrated Biopharma's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.
Other Consideration for investing in Integrated OTC Stock
If you are still planning to invest in Integrated Biopharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Integrated Biopharma's history and understand the potential risks before investing.
Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
Commodity Channel Use Commodity Channel Index to analyze current equity momentum |